News Features Reimbursement Issues Seem to Be Holding Renal Denervation Back Todd Neale December 19, 2024
News Daily News Study Supports Cost-effectiveness of Renal Denervation for Hypertension Todd Neale August 23, 2024
News Daily News Symplicity Spyral Approved: FDA Clears Second Renal Denervation System Todd Neale November 20, 2023
News Features Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar L.A. McKeown May 12, 2023
News Daily News Reduction in BP Drives Treatment Preference for Hypertensive Patients Michael O'Riordan December 20, 2022
News Daily News RADIANCE II Top-Line Results Promising for Ultrasound Renal Denervation Todd Neale July 26, 2022
News Daily News FDA Issues New Guidance on Sodium Targets for Food Industry L.A. McKeown October 14, 2021
News Daily News Renal Denervation a Third Option for Hypertension, European Experts Say Todd Neale September 17, 2021
News Daily News FDA: Some Tainted Losartan Must Remain on US Market to Maintain Adequate Access for Patients L.A. McKeown March 21, 2019
News Daily News FDA Provides Update on Tainted ARB Investigation, With New Impurity Found Todd Neale March 04, 2019
News Features The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine Shelley Wood October 22, 2018
News Daily News FDA’s Proposed Sodium Reduction Plan Could Have a Big Impact, Analysis Suggests Todd Neale April 11, 2018
News Daily News Cardiology Groups Applaud FDA’s Draft Guidance Setting Voluntary Sodium Cuts for Processed Food Industry Shelley Wood June 01, 2016